Jessica M. Wiwczar

Jessica M. Wiwczar

Auto-generated profile, based on publicly available information

Jessica M. Wiwczar

Invenra Inc. Madison WI

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2022 in Photosynthesis Research
Verified
Journal Article
Closed access
PDF file
DFDavid A. Flesher
David A. Flesher
JLJinchan Liu
Jinchan Liu
JWJessica M. Wiwczar
Jessica M. Wiwczar
KRKrystle Reiss
Krystle Reiss
KYKe R. Yang
Ke R. Yang
Gary W. BrudvigGary W. Brudvig
Gary W. Brudvig

28 May 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
AEAmy K. Erbe
Amy K. Erbe
AFArika S. Feils
Arika S. Feils
AHAlina Hampton
Alina Hampton
ZRZachary T Rosenkrans
Zachary T Rosenkrans
MFMildred Felder
Mildred Felder
PSPaul Sondel
Paul Sondel
The current treatment for neuroblastoma involves an immunotherapy regimen that includes a monoclonal antibody that recognizes disialoganglioside (GD2), expressed at high levels on neuroblastoma. GD2 is not present on most normal tissues but is expressed on nerves. Thus, anti-GD2 treatment causes substantial, dose-limiting, neuropathic pain. B7-H3 is overexpressed on multiple tumor types, including neuroblastoma, with minimal normal cell expression and is absent on nerves. We designed a bispecific antibody (bsAb) that requires simultaneous binding of these two tumor antigens to achieve tight-binding of tumor cells. Our preclinical research shows that when compared to an anti-GD2 monospecific antibody, the GD2xB7-H3 bsAb has improved tumor specificity with similar efficacy and reduced toxicity. Since this bsAb does not bind to nerves, it may be possible to administer increased or additional doses beyond the tolerable dose of monospecific anti-GD2 antibodies, which could improve therapeutic efficacy and quality of life for patients with neuroblastoma.